{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:32:52Z","timestamp":1790767972799,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s11920-017-0759-9","type":"journal-article","created":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T02:33:29Z","timestamp":1486434809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Juvenile Huntington\u2019s Disease: Diagnostic and Treatment Considerations for the Psychiatrist"],"prefix":"10.1007","volume":"19","author":[{"given":"Joanna","family":"Quigley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,7]]},"reference":[{"issue":"6","key":"759_CR1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"The Huntington\u2019s Disease Collaborative Research Group","year":"1993","unstructured":"The Huntington\u2019s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell. 1993;72(6):971\u201383.","journal-title":"Cell"},{"key":"759_CR2","volume":"3","author":"I Douglas","year":"2013","unstructured":"Douglas I, Evans S, Rawlins MD, Smeeth L, Tabrizi SJ, Wexler NS. Juvenile Huntington\u2019s disease: a population-based study using the General Practice Research Database. BMJ Open. 2013;3, e002085.","journal-title":"BMJ Open"},{"issue":"14","key":"759_CR3","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/mds.25237","volume":"27","author":"LJ Cloud","year":"2012","unstructured":"Cloud LJ, Rosenblatt A, Margolis RL, Ross CA, Pillai JA, Corey-Bloom H, et al. Seizures in juvenile Huntington\u2019s disease: frequency and characterization in a multicenter cohort. Mov Disord. 2012;27(14):1797\u2013800.","journal-title":"Mov Disord"},{"key":"759_CR4","doi-asserted-by":"crossref","unstructured":"Letort D, Gonzalez-Alegre P. Huntington's disease in children. Handb Clin Neurol. 2013;113:1913\u20137.","DOI":"10.1016\/B978-0-444-59565-2.00061-7"},{"issue":"5","key":"759_CR5","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4103\/1673-5374.182682","volume":"11","author":"P Deng","year":"2016","unstructured":"Deng P, Torrest A, Pollock K, Dahlenburg H, Annett G, Nolta JA, et al. Clinical trial perspective for adult and juvenile Huntington\u2019s disease using genetically-engineered mesenchymal stem cells. Neural REgen Res. 2016;11(5):702\u20135.","journal-title":"Neural REgen Res"},{"key":"759_CR6","doi-asserted-by":"crossref","first-page":"e4f8606b742ef3","DOI":"10.1371\/4f8606b742ef3","volume":"4","author":"O Quarrell","year":"2012","unstructured":"Quarrell O, O\u2019Donovan KL, Bandmann O, Strong M. The prevalence of juvenile Huntington\u2019s disease: a review of the literature and meta-analysis. PLos Curr. 2012;4:e4f8606b742ef3.","journal-title":"PLos Curr"},{"key":"759_CR7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/jnnp.66.1.52","volume":"66","author":"T Faroud","year":"1999","unstructured":"Faroud T, Gray J, Ivashina J, Conneally PM. Differences in duration of Huntington\u2019s disease based on age at onset. J Neurol Neurosurg Psychiatry. 1999;66:52\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"759_CR8","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/hmg\/2.10.1535","volume":"2","author":"H Telenius","year":"1993","unstructured":"Telenius H, Kremer HPH, Theilmann J, Andrew SE, Almqvist E, Anvret M, et al. Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Human Mol Gen. 1993;2(10):1535\u201340.","journal-title":"Human Mol Gen"},{"key":"759_CR9","doi-asserted-by":"crossref","unstructured":"Nicholas G, Devys D, Goldenberg A, Maltete D, Herve C, Hannequin D, Guyant-Marechal L. Juvenile Huntington disease in a 18-month-old boy revealed by global developmental dealy and reduced cerebellar volume. Am J Med Genet 2011;Part A 155:815-818.","DOI":"10.1002\/ajmg.a.33911"},{"key":"759_CR10","first-page":"436","volume":"34","author":"YP Chuo","year":"2012","unstructured":"Chuo YP, Hou PH, Chan CH, Lin CC, Liao YC. Juvenile Huntington\u2019s disease presenting as difficult-to-treat seizure and the first episode of psychosis. Gen Hosp Psych. 2012;34:436. e9-436.e11.","journal-title":"Gen Hosp Psych"},{"key":"759_CR11","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archneur.64.6.813","volume":"64","author":"P Riba\u00ef","year":"2007","unstructured":"Riba\u00ef P, Nguyen K, Hahn-Barma V, Gourfinkel-An I, Vidailhet M, Legout A, et al. Psychiatric and cognitive difficulties as indicators of juvenile Huntington disease onset in 29 pateints. Arch Neurol. 2007;64:813\u20139.","journal-title":"Arch Neurol"},{"key":"759_CR12","unstructured":"Kliegman RM, Behrman RE, Jenson HB, Stanton BF Ed. Nelson Textbook of pediatrics. 18th ed. Philadelphia: W.B. Saunders Co; 2007. p. 2488\u20132493."},{"issue":"9","key":"759_CR13","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/mds.22876","volume":"25","author":"SC Lai","year":"2010","unstructured":"Lai SC, Jung SM, Grattan-Smith P, Sugo E, Lin YW, Chen RS, et al. Neuronal intranuclear inclusion disease: two cases of dopa-responsive juvenile parkinsonism with drug-induced dyskinesia. Mov Disord. 2010;25(9):1274\u20139.","journal-title":"Mov Disord"},{"key":"759_CR14","doi-asserted-by":"crossref","unstructured":"Robertson L, Santini H, O\u2019Donovan KL. Squitieri F, Barker RA, Rakowicz M, Landwehrmeyer GB, Quarrell O. Current pharmacological management in juvenile Huntington\u2019s disease. PLoS Curr 2012 Feb 6 [revised 2012 Mar 26];4:RRN1304.","DOI":"10.1371\/currents.RRN1304"},{"key":"759_CR15","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1055\/s-2000-7461","volume":"31","author":"A Rasmussen","year":"2000","unstructured":"Rasmussen A, Macias R, Ochoa A, Davila G, Alonso E. Huntington disease in children: genotype-phenotype correlation. Neuropediatrics. 2000;31:190\u20134.","journal-title":"Neuropediatrics"},{"key":"759_CR16","doi-asserted-by":"crossref","unstructured":"Quarrell OW, Nance MA, Nopoulos P, Paulsen JS, Smith JA, Squitieri F. Managing juvenile Huntington\u2019s disease. Neurodegner Dis Manag 2013 June 1;3(3):.doi10.2217\/nmt.13.18.","DOI":"10.2217\/nmt.13.18"},{"issue":"9","key":"759_CR17","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1080\/14737175.2016.1196139","volume":"16","author":"L Biase di","year":"2016","unstructured":"di Biase L, Munhoz RP. Deep brain stimulation for the treatment of hyperkinetic movement disorders. Exp Rev Neurotherapeutics. 2016;16(9):1067\u201378. doi: 10.1080\/14737175.2016.1196139 . Epub 2016 Jun 10.","journal-title":"Exp Rev Neurotherapeutics"},{"key":"759_CR18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.brainresbull.2006.10.028","volume":"72","author":"EH Aylward","year":"2007","unstructured":"Aylward EH. Change in MRI striatal volumes as a biomarker in preclinical Huntington\u2019s disease. Brain Res Bull. 2007;72:152\u20138.","journal-title":"Brain Res Bull"},{"issue":"5","key":"759_CR19","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2217\/rme.15.25","volume":"10","author":"KD Fink","year":"2015","unstructured":"Fink KD, Deng P, Torrest A, Stewart H, Pollack K, Gruenloh W, et al. Developing stem cell therapies for juvenile and adult-onset Huntington\u2019s disease. Regen Med. 2015;10(5):623\u201346. Review of research into the use of mesenchymal stem cells and BDNF in the treatment of Huntington\u2019s disease.","journal-title":"Regen Med"},{"key":"759_CR20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2310\/7010.2006.00055","volume":"21","author":"P Gonzalez-Alegre","year":"2006","unstructured":"Gonzalez-Alegre P, Afifi AK. Clinical characteristics of childhood-onset (juvenile) Huntington disease: report of 12 patients and review of the literature. J Child Neurol. 2006;21:223\u20139.","journal-title":"J Child Neurol"},{"key":"759_CR21","doi-asserted-by":"crossref","unstructured":"Reilmann R, Leavitt BR, Ross CA. Diagnostic criteria for Huntington's disease based on natural history. Mov Disord. 2014;29(11):1335\u201341.","DOI":"10.1002\/mds.26011"},{"key":"759_CR22","doi-asserted-by":"publisher","unstructured":"Orth M, Handley OJ, Shwenke C, Dunnett SB, Craufurd D, Ho AK, Wild E, Tabrizi SJ, Landwehrmeyer GB. Observing Huntington\u2019s disease: the European Huntington\u2019s Disease Registry. PloS Curr 2010 September 28 [revised 2011 April 13]; Published online 2011 April 13. doi: 10.1371\/currents.RRN1184","DOI":"10.1371\/currents.RRN1184"},{"issue":"2","key":"759_CR23","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"Huntington Study Group","year":"1996","unstructured":"Huntington Study Group. Unified Huntington\u2019s disease rating scale: reliability and consistency. Mov Disord. 1996;11(2):136\u201342.","journal-title":"Mov Disord"},{"key":"759_CR24","doi-asserted-by":"publisher","unstructured":"Mestre TA et al. Rating scales for behavioral symptoms in Huntington\u2019s disease: critique and recommendations. Movement Disorders 2016 doi: 10.1002\/mds.26675 . Highlighted the limitations of existing rating scales considering the complexity of behavioral symptoms in Huntington\u2019s disease","DOI":"10.1002\/mds.26675"},{"key":"759_CR25","doi-asserted-by":"crossref","unstructured":"The Huntington Study Group. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316(1):40\u201350. Trial of a novel therapy for treatment of chorea.","DOI":"10.1001\/jama.2016.8655"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-017-0759-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11920-017-0759-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-017-0759-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T17:08:06Z","timestamp":1658596086000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11920-017-0759-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["759"],"URL":"https:\/\/doi.org\/10.1007\/s11920-017-0759-9","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]},"article-number":"9"}}